CN115353465A - Synthesis method of neostigmine methylsulfate - Google Patents

Synthesis method of neostigmine methylsulfate Download PDF

Info

Publication number
CN115353465A
CN115353465A CN202211302439.0A CN202211302439A CN115353465A CN 115353465 A CN115353465 A CN 115353465A CN 202211302439 A CN202211302439 A CN 202211302439A CN 115353465 A CN115353465 A CN 115353465A
Authority
CN
China
Prior art keywords
compound
neostigmine
acid
mol
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211302439.0A
Other languages
Chinese (zh)
Inventor
谭奇
丁从虎
覃东庆
蒋正富
刘平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunnan Xianshi Pharmaceutical Co ltd
Original Assignee
Yunnan Xianshi Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunnan Xianshi Pharmaceutical Co ltd filed Critical Yunnan Xianshi Pharmaceutical Co ltd
Priority to CN202211302439.0A priority Critical patent/CN115353465A/en
Publication of CN115353465A publication Critical patent/CN115353465A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/24—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfuric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The invention relates to a synthesis method of neostigmine methosulfate, which comprises the following steps,
Figure 157574DEST_PATH_IMAGE001
the synthesis method has the advantages of simple process, short reaction time, high efficiency, high yield, mild reaction conditions and low cost, and is suitable for industrial productionAnd (4) large-scale production.

Description

Synthesis method of neostigmine methylsulfate
Technical Field
The invention relates to the field of drug synthesis, in particular to a synthesis method of neostigmine mesylate.
Background
Neostigmine mesylate is an injection of neostigmine. The indications are anticholinesterase drugs. Antagonize residual muscle relaxation effect of non-depolarizing muscle relaxants at the end of surgery, and can be used for myasthenia gravis, functional intestinal distention and urinary retention after surgery, etc. The product can inhibit cholinesterase activity to exert cholinomimetic effect, and can directly stimulate nicotinic receptor (N2 receptor) on skeletal muscle motor end plate. The medicine has the advantages of weak effect on gland, eye, cardiovascular and bronchial smooth muscle, capability of promoting gastric contraction and increasing gastric acid secretion on gastrointestinal smooth muscle, and capability of promoting peristalsis of small intestine and large intestine, especially colon, thereby preventing intestinal canal from relaxing and promoting intestinal contents to push downwards. It has strong exciting action on skeletal muscle but weak action on central nervous system.
The preparation process of neostigmine mesylate is reported IN indian patent IN1078MUM2014A, the route of which is briefly described below.
Figure 80311DEST_PATH_IMAGE001
When two methyl groups on dimethyl sulfate are utilized on aniline in the reaction of step 1 in the scheme of the patent documents, the reaction is easy to stay in an intermediate state, namely a byproduct generated when one methyl group is on an amino group, the reaction is slow, quaternary ammonium salt is easy to generate at the end point of the reaction, the product yield is low, and the purification difficulty is high. In the 3 rd step of the route, alkali is not used as an acid-binding agent, the reaction is slow, and the by-product obtained after methylation of dimethyl sulfate is strong in acidity, so that problems such as hydrolysis of neostigmine methylsulfate and the like are easily caused. The method has the advantages of low reaction yield, high purification difficulty and high risk of subsequent industrial amplification.
Disclosure of Invention
In view of the above problems, an object of the present invention is to provide a method for synthesizing neostigmine mesylate.
The application provides a preparation method of neostigmine mesylate, which comprises the following synthetic route:
Figure 145219DEST_PATH_IMAGE002
the synthesis method has the advantages of simple process, short reaction time, high efficiency, high yield, mild reaction conditions and low cost, and is suitable for industrial scale-up production. The quality of the prepared neostigmine mesylate completely meets the requirements of pharmacopoeia, and the quality and the medication safety of the medicine can be ensured.
Drawings
FIG. 1 is a hydrogen spectrum of Compound 1.
Fig. 2 is a carbon spectrum of compound 1.
FIG. 3 is a substance diagram of Compound 1.
FIG. 4 is a hydrogen spectrum of Compound 2.
Fig. 5 is a carbon spectrum of compound 2.
FIG. 6 is a substance diagram of Compound 2.
FIG. 7 is a hydrogen spectrum of Compound 3.
Fig. 8 is a carbon spectrum of compound 3.
FIG. 9 shows the substance pattern of Compound 3.
FIG. 10 is a hydrogen spectrum of Compound 4.
FIG. 11 is a carbon spectrum of Compound 4.
FIG. 12 is a substance diagram of Compound 4.
Detailed Description
In order to make the technical solution and advantages of the present invention more comprehensible, a detailed description is given below by way of specific examples.
In one aspect, the present application provides a method for preparing neostigmine mesylate, comprising the following synthetic route:
Figure 481653DEST_PATH_IMAGE002
wherein PG is an amino protecting group;
reacting the compound 1 with dimethylamino formyl chloride, an acid-binding agent and a catalyst in the step 1 to obtain a compound 2;
in the step 2, a compound 2 is subjected to deamination Protecting Group (PG) to obtain a compound 3;
and (4) reacting the compound 3 with a methylation reagent and an acid-binding agent in the step (3) to obtain a compound 4.
In some embodiments, the PG is selected from the group consisting of alkoxycarbonyl protecting groups, acyl protecting groups, and alkyl protecting groups, such as benzyloxycarbonyl (Cbz), tert-butoxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc).
In some embodiments, the catalyst in step 1 is selected from one or more of 4-dimethylaminopyridine, pyridine, and imidazole.
In some embodiments, an acid is added to remove the protecting group in step 2, for example, the acid added is concentrated hydrochloric acid, ethanolic hydrogen chloride solution, ethyl acetate hydrogen chloride solution.
In some embodiments, the methylating agent in step 3 is selected from one or more of dimethyl sulfate, methyl iodide and methyl bromide.
In some embodiments, the method for preparing neostigmine mesylate comprises the following synthetic route:
Figure 177077DEST_PATH_IMAGE003
wherein PG is tert-butyloxycarbonyl (Boc);
reacting the compound 1 with dimethylcarbamoyl chloride, an acid-binding agent and 4-dimethylaminopyridine in the step 1 to obtain a compound 2;
in the step 2, a compound 2 is subjected to deamination Protecting Group (PG) to obtain a compound 3;
and 3, reacting the compound 3 with dimethyl sulfate and an acid-binding agent to obtain a compound 4.
In some embodiments, the molar ratio of compound 1 to catalyst in step 1 is 1 (0.1-0.5), such as 1.
In some embodiments, the molar ratio of compound 1 to 4-dimethylaminopyridine in step 1 is 1 (0.1-0.5), such as 1.
In some embodiments, the molar ratio of compound 1 to acid scavenger in step 1 is 1: (1.0-2.0), for example 1: 1.0, 1: 1.1, 1: 1.2, 1: 1.3, 1: 1.4, 1: 1.5, 1: 1.6, 1: 1.7, 1: 1.8, 1: 1.9, 1: 2.0.
In some embodiments, the molar ratio of compound 2 to acid in step 2 is 1 (0.6-1.5), e.g., 1: 0.6, 1: 0.7, 1: 0.8, 1: 0.9, 1: 1.0, 1: 1.1, 1: 1.2, 1: 1.3, 1: 1.4, 1: 1.5.
In some embodiments, the reaction temperature in step 2 is 0-50 ℃, preferably 30 ℃.
In some embodiments, the molar ratio of compound 3 to methylating agent in step 3 is 1 (3.0-5.0), such as 1.
In some embodiments, the molar ratio of compound 3 to dimethyl sulfate in step 3 is 1 (3.0-5.0), such as 1.
In some embodiments, the molar ratio of compound 3 to acid scavenger in step 3 is 1: (2.0-4.0), such as 1.
In some embodiments, the reaction temperature in step 3 is 20 to 60 ℃, preferably 40 ℃.
In some embodiments, the acid-binding agent includes an organic or inorganic base, which is used to neutralize the acid generated in the reaction system and promote the forward reaction, and may be one or more selected from triethylamine, DIEA, pyridine, sodium acetate, sodium carbonate, potassium carbonate, and calcium carbonate.
In some embodiments, the acid-binding agent in step 1 is selected from bases capable of reacting with HCl generated in step 1, such as one or more of sodium carbonate, potassium carbonate, triethylamine, DIEA, pyridine, sodium acetate, calcium carbonate, preferably one or more of sodium carbonate, potassium carbonate, and triethylamine.
In some embodiments, the acid-binding agent in step 3 is selected from a base capable of reacting with sulfuric acid or methylsulfuric acid generated in step 3, such as one or more of sodium carbonate, potassium carbonate, calcium carbonate, triethylamine, DIEA, pyridine, and sodium acetate, preferably one or more of sodium carbonate, potassium carbonate, and calcium carbonate.
In some embodiments, the compound 1 is obtained by introducing an amino Protecting Group (PG) through m-aminophenol
Figure 497331DEST_PATH_IMAGE004
。
In some embodiments, m-aminophenol is reacted with a BOC anhydride (di-tert-butyl dicarbonate) to provide compound 1.
In some embodiments, the molar ratio of m-aminophenol to BOC anhydride is 1 (1.0-1.5), such as 1: 1.0, 1: 1.1, 1: 1.2, 1: 1.3, 1: 1.4, 1: 1.5.
In some embodiments, the step 1 intermediate aminophenol is reacted with the BOC anhydride at a temperature of 30 to 70 ℃, preferably 50 ℃.
In some embodiments, the BOC anhydride is added dropwise into the reaction system in step 1.
Preparation of Compound 1 (tert-butyl 3-Hydroxyphenylcarbamate)
Figure 38033DEST_PATH_IMAGE005
Example 1:
adding 50.0g (about 0.46 mol) of m-aminophenol and 250ml of ethyl acetate into a 1000ml reaction bottle, heating to 30 ℃, slowly adding 100.0g (about 0.46 mol) of BOC acid anhydride dropwise, keeping the temperature at 50 ℃ for reaction for 3 hours after the dropwise addition is finished, concentrating under reduced pressure by using a rotary evaporator to obtain an oily substance, adding 250ml of n-heptane, keeping the temperature at 50 ℃ for crystallization for 1 hour, cooling to room temperature, filtering to obtain a wet product of the compound 1, drying the wet product in vacuum at 50 ℃ for 4 hours to obtain 88.2g of the compound 1 totally, wherein the HPLC purity is more than 99.5%.
Example 2:
adding 50.0g (about 0.46 mol) of m-aminophenol and 250ml of ethyl acetate into a 1000ml reaction bottle, heating to 30 ℃, slowly adding 150.0g (about 0.69 mol) of BOC anhydride dropwise, keeping the temperature at 50 ℃ for reaction for 3 hours after the dropwise addition is finished, concentrating the mixture into oily matter under reduced pressure by using a rotary evaporator, adding 250ml of n-heptane, keeping the temperature at 50 ℃ for crystallization for 1 hour, cooling to room temperature, filtering to obtain a wet product of the compound 1, drying the wet product in vacuum at 50 ℃ for 4 hours to obtain 93.0g of the compound 1 totally, wherein the HPLC purity is more than 99.5%.
The hydrogen spectrogram, the carbon spectrogram and the related substance chart of the compound 1 prepared by the application are respectively shown in figures 1 to 3.
Preparation of compound 2 (3- ((tert-butoxycarbonyl) amino) phenyl dimethylcarbamate)
Figure 9401DEST_PATH_IMAGE006
Example 3:
80.0g (about 0.38 mol) of the compound 1, 9.1g (about 0.076 mol) of 4-dimethylaminopyridine, 58.0g (about 0.57 mol) of triethylamine and 500ml of ethyl acetate are added into a 1000ml reaction bottle, the temperature is reduced to 10 ℃, 61.7g (about 0.57 mol) of dimethylcarbamoyl chloride is slowly dripped, the dripping is finished, the temperature is kept at 10 ℃ for reaction for 12 hours, the temperature is reduced to-10 ℃, white wet products are obtained by filtration, the wet products are beaten for 1 hour by 500ml of purified water, the wet products of the compound 2 are obtained by filtration, the wet products are placed at 50 ℃ for vacuum drying for 8 hours, the total 101.8g of the compound 1 is obtained, and the HPLC purity is more than 99.8 percent.
Example 4:
adding 80.0g (about 0.38 mol) of the compound 1, 9.1g (about 0.076 mol) of 4-dimethylaminopyridine, 58.0g (about 0.57 mol) of triethylamine and 500ml of ethyl acetate into a 1000ml reaction bottle, cooling to 10 ℃, slowly adding 61.7g (about 0.57 mol) of dimethylcarbamoyl chloride dropwise, keeping the temperature for 10 ℃ for reaction for 12 hours, cooling to 0 ℃, filtering to obtain a white wet product, pulping the wet product with 500ml of purified water for 1 hour, filtering to obtain a compound 2 wet product, placing the wet product at 50 ℃ for vacuum drying for 8 hours to obtain 91.2g of the compound 1 totally, wherein the HPLC purity is more than 99.8 percent.
Example 5:
adding 80.0g (about 0.38 mol) of compound 1, 9.1g (about 0.076 mol) of 4-dimethylaminopyridine, 30.4g (about 0.29 mol) of sodium carbonate and 500ml of ethyl acetate into a 1000ml reaction bottle, cooling to 10 ℃, slowly adding 61.7g (about 0.57 mol) of dimethylcarbamoyl chloride dropwise, keeping the temperature for 10 ℃ for reaction for 24 hours, cooling to-10 ℃, filtering to obtain a white wet product, pulping the wet product with 500ml of purified water for 1 hour, filtering to obtain a compound 2 wet product, placing the wet product at 50 ℃ for vacuum drying for 8 hours to obtain 95.2g of compound 1 totally, wherein the HPLC purity is more than 99.8%.
Example 6:
adding 80.0g (about 0.38 mol) of the compound 1, 9.1g of 4-dimethylaminopyridine (about 0.076 mol), 39.6g of potassium carbonate (about 0.29 mol) and 500ml of ethyl acetate into a 1000ml reaction bottle, cooling to 10 ℃, slowly adding 61.7g (about 0.57 mol) of dimethylcarbamoyl chloride dropwise, keeping the temperature for 10 ℃ for reaction for 24 hours, cooling to-10 ℃, filtering to obtain a white wet product, pulping the wet product for 1 hour by using 500ml of purified water, filtering to obtain a compound 2 wet product, placing the wet product at 50 ℃ for vacuum drying for 8 hours to obtain 75.5g of the compound 1 in total, wherein the HPLC purity is more than 99.8%.
The hydrogen spectrogram, the carbon spectrogram and the related substance chart of the compound 2 prepared by the application are respectively shown in figures 4-6.
Preparation of Compound 3 (3-aminophenyldimethylcarbamate)
Figure 352090DEST_PATH_IMAGE007
Example 7:
a500 ml reaction flask was charged with 60.0g (about 0.21 mol) of Compound 2 and 300ml of ethyl acetate, heated to 30 ℃ and added with 36.0g of an ethanol solution of hydrogen chloride (concentration: 8 mol/L) dropwise, reacted at 30 ℃ for 6 hours, and then neutralized and separated with a 20% sodium carbonate solution. Separating out an organic phase, concentrating the organic phase into oily matter by using a rotary evaporator under reduced pressure, adding 300ml of n-heptane into the oily matter, crystallizing the oily matter for 1 hour, filtering the oily matter to obtain a wet product of the compound 3, placing the wet product at 50 ℃ and drying the wet product in vacuum for 4 hours to obtain the compound 3, wherein the total mass is 36.6g, and the HPLC purity is more than 99.9%.
Example 8:
adding 60.0g (about 0.21 mol) of compound 2 and 100ml of absolute ethyl alcohol into a 1000ml reaction bottle, heating to 30 ℃, dropwise adding 36.0g of hydrogen chloride ethanol solution (the concentration is 8 mol/L), reacting for 6 hours at the temperature of 30 ℃, and removing the ethanol by decompression and concentration by a rotary evaporator after the reaction is finished; 300ml of ethyl acetate was added, followed by neutralization with a 20% sodium carbonate solution and liquid separation. Separating out organic phase, concentrating under reduced pressure with rotary evaporator to obtain oily substance, adding 300ml n-heptane into oily substance, crystallizing for 1 hr, filtering to obtain wet product of compound 3, vacuum drying at 50 deg.C for 4 hr to obtain compound 3 with purity of over 99.9% by HPLC (35.6 g).
Example 9:
a1000 ml reaction flask was charged with 60.0g (about 0.21 mol) of Compound 2 and 300ml of ethyl acetate, heated to 30 ℃ and then added with 36.0g of concentrated hydrochloric acid dropwise, after completion of the reaction at 30 ℃ for 6 hours, the reaction mixture was neutralized with a 20% sodium carbonate solution and separated. Separating out organic phase, concentrating under reduced pressure by using a rotary evaporator to obtain oily substance, adding 300ml of n-heptane into the oily substance, crystallizing for 1 hour, filtering to obtain a wet product of the compound 3, placing the wet product at 50 ℃ and drying in vacuum for 4 hours to obtain the compound 3, wherein the total amount of 31.9g and the HPLC purity is more than 99.9%.
Example 10:
a1000 ml reaction flask was charged with 60.0g (about 0.21 mol) of Compound 2 and 100ml of ethyl acetate, the temperature was raised to 30 ℃ and 72.0g of ethyl acetate hydrochloride (concentration: 4 mol/L) was added dropwise thereto, and after completion of the reaction at 30 ℃ for 8 hours, the reaction was terminated and neutralized with a 20% sodium carbonate solution and separated. Separating out organic phase, concentrating under reduced pressure by using a rotary evaporator to obtain oily substance, adding 300ml of n-heptane into the oily substance, crystallizing for 1 hour, filtering to obtain a wet product of the compound 3, placing the wet product at 50 ℃ and drying in vacuum for 4 hours to obtain the compound 3, wherein the total amount of 36.9g and the HPLC purity is more than 99.9%.
The hydrogen spectrogram, the carbon spectrogram and the related substance chart of the compound 3 prepared by the application are respectively shown in figures 7 to 9.
Preparation of Compound 4 (neostigmine Methylsulfate)
Figure 408907DEST_PATH_IMAGE008
Example 11:
a1000 ml reaction flask was charged with 30.0g (about 0.17 mol) of Compound 3, 35.3g (about 0.33 mol) of sodium carbonate, 150ml of acetonitrile, 63.0g (about 0.50 mol) of dimethyl sulfate was added dropwise at 20 ℃ and, after completion of the addition, the temperature was raised to 40 ℃ and the reaction was allowed to proceed for 6 hours. After the reaction is finished, inorganic salt is filtered out, the filtrate is decompressed and concentrated into oily matter by a rotary evaporator, 150ml of ethyl acetate is added for crystallization for 1 hour, wet product is obtained by filtration, the wet product is placed at 50 ℃ for vacuum drying for 4 hours, 50.6g of neostigmine mesylate is obtained, the HPLC purity is more than 99.9 percent, and the single impurity is less than 0.05 percent.
Example 12:
a1000 ml reaction flask was charged with 30.0g (about 0.17 mol) of Compound 3, 35.3g (about 0.33 mol) of sodium carbonate, 150ml of acetonitrile, 105.0.0g (about 0.83 mol) of dimethyl sulfate was added dropwise at 20 ℃ and, after completion of the addition, the temperature was raised to 40 ℃ and the reaction was allowed to proceed for 2 hours. After the reaction is finished, inorganic salt is filtered out, the filtrate is decompressed and concentrated into oily matter by a rotary evaporator, 150ml of ethyl acetate is added for crystallization for 1 hour, wet product is obtained by filtration, the wet product is placed at 50 ℃ for vacuum drying for 4 hours, 53.6g of neostigmine mesylate is obtained, the HPLC purity is more than 99.9 percent, and the single impurity is less than 0.05 percent.
Example 13:
a1000 ml reaction flask was charged with 30.0g (about 0.17 mol) of Compound 3, 35.3g (about 0.33 mol) of sodium carbonate, 150ml of acetone, 105.0.0g (about 0.83 mol) of dimethyl sulfate was added dropwise at 20 ℃ and, after completion of the addition, the temperature was raised to 40 ℃ and the reaction was allowed to proceed for 2 hours. After the reaction is finished, inorganic salt is filtered out, the filtrate is decompressed and concentrated into oily matter by a rotary evaporator, 150ml of ethyl acetate is added for crystallization for 1 hour, wet product is obtained after filtration, the wet product is placed at 50 ℃ for vacuum drying for 4 hours, 45.4g of neostigmine mesylate is obtained, the HPLC purity is 99.9 percent, and the single impurity is less than 0.05 percent.
Example 14:
a1000 ml reaction flask was charged with 30.0g (about 0.17 mol) of Compound 3, 46.0g (about 0.33 mol) of potassium carbonate, 150ml of acetonitrile, 105.0.0g (about 0.83 mol) of dimethyl sulfate was added dropwise at 20 ℃ and, after completion of the addition, the temperature was raised to 40 ℃ and the reaction was allowed to proceed for 2 hours. After the reaction is finished, inorganic salt is filtered out, the filtrate is decompressed and concentrated into oily matter by a rotary evaporator, 150ml of ethyl acetate is added for crystallization for 1 hour, wet product is obtained after filtration, the wet product is placed at 50 ℃ for vacuum drying for 4 hours, 52.7g of neostigmine mesylate is obtained, the HPLC purity is more than 99.9 percent, and the single impurity is less than 0.05 percent.
Example 15:
a1000 ml reaction flask was charged with 30.0g (about 0.17 mol) of Compound 3, 66.6g (about 0.67 mol) of calcium carbonate, 150ml of acetonitrile, 105.0.0g (about 0.83 mol) of dimethyl sulfate was added dropwise at 20 ℃ and, after completion of the addition, the temperature was raised to 40 ℃ and the reaction was allowed to proceed for 2 hours. After the reaction is finished, inorganic salt is filtered out, the filtrate is decompressed and concentrated into oily matter by a rotary evaporator, 150ml of ethyl acetate is added for crystallization for 1 hour, wet product is obtained after filtration, the wet product is placed at 50 ℃ for vacuum drying for 4 hours, 54.7g of neostigmine mesylate is obtained, the HPLC purity is more than 99.9 percent, and the single impurity is less than 0.05 percent.
The hydrogen spectrum, the carbon spectrum and the related substance map of the compound 4 prepared by the application are respectively shown in figures 10-12.
It should be understood that the above embodiments are exemplary and are not intended to encompass all possible implementations encompassed by the claims. Various modifications and changes may also be made on the basis of the above embodiments without departing from the scope of the present disclosure. Likewise, various features of the above embodiments may also be combined in any combination to form additional embodiments of the invention that may not be explicitly described. Therefore, the above examples only represent some embodiments of the present invention, and do not limit the scope of the present invention.

Claims (10)

1. The preparation method of neostigmine mesylate is characterized by comprising the following synthetic route:
step 1: reacting the compound 1 with dimethylcarbamoyl chloride, an acid-binding agent and a catalyst to obtain a compound 2;
step 2: compound 2 is deaminated to form a compound 3;
and step 3: reacting the compound 3 with a methylation reagent and an acid-binding agent to obtain a compound 4;
the reaction equation is as follows:
Figure 142293DEST_PATH_IMAGE001
wherein PG is an amino protecting group.
2. The process for producing neostigmine methosulfate according to claim 1,
the mol ratio of the compound 1 to the catalyst in the step 1 is 1 (1.0-2.0);
the mol ratio of the compound 1 to the 4-dimethylaminopyridine in the step 1 is 1 (0.1-0.5);
the molar ratio of the compound 1 to the acid-binding agent in the step 1 is 1 (1.0-2.0);
the mol ratio of the compound 3 to the methylating agent in the step 3 is 1 (3.0-5.0);
the molar ratio of the compound 3 to the acid binding agent in the step 3 is 1 (2.0-4.0).
3. A process for preparing neostigmine mesylate according to any one of claims 1 to 2, wherein the catalyst in step 1 is selected from the group consisting of 4-dimethylaminopyridine, pyridine and imidazole.
4. A process for the preparation of neostigmine methosulfate according to any one of claims 1-2, wherein the methylating agent in step 3 is selected from one or more of dimethyl sulfate, methyl iodide and methyl bromide.
5. A process for the preparation of neostigmine methosulfate according to any of claims 1-2, wherein the acid scavenger is selected from one or more of triethylamine, DIEA, pyridine, sodium acetate, sodium carbonate, potassium carbonate and calcium carbonate.
6. The method for preparing neostigmine mesylate according to claim 5, wherein the acid-binding agent in the step 1 is one or more selected from the group consisting of sodium carbonate, potassium carbonate and triethylamine.
7. The method for preparing neostigmine mesylate according to claim 5, wherein the acid-binding agent in the step 3 is one or more selected from sodium carbonate, potassium carbonate and calcium carbonate.
8. A process for the preparation of neostigmine mesylate according to any one of claims 1 to 2, wherein PG is selected from the group consisting of an alkoxycarbonyl protecting group, an acyl protecting group and an alkyl protecting group.
9. A process for preparing neostigmine methosulfate according to claim 8, wherein PG is selected from benzyloxycarbonyl, tert-butoxycarbonyl and 9-fluorenylmethyloxycarbonyl.
10. The method of preparing neostigmine mesylate according to claim 1, wherein an acid is added to remove a protecting group in step 2.
CN202211302439.0A 2022-10-24 2022-10-24 Synthesis method of neostigmine methylsulfate Pending CN115353465A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211302439.0A CN115353465A (en) 2022-10-24 2022-10-24 Synthesis method of neostigmine methylsulfate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211302439.0A CN115353465A (en) 2022-10-24 2022-10-24 Synthesis method of neostigmine methylsulfate

Publications (1)

Publication Number Publication Date
CN115353465A true CN115353465A (en) 2022-11-18

Family

ID=84008816

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211302439.0A Pending CN115353465A (en) 2022-10-24 2022-10-24 Synthesis method of neostigmine methylsulfate

Country Status (1)

Country Link
CN (1) CN115353465A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010130899A (en) * 2010-07-23 2012-01-27 Федеральное Государственное Учреждение "33 Центральный Научно-Исследовательский Испытательный Институт Министерства Обороны Российск METHOD FOR PRODUCING NEOSTIGMINE METHYL SULPHATE AND NEOSTIGMINE IODIDE
WO2017175238A1 (en) * 2016-04-07 2017-10-12 Neon Laboratories Limited Highly chemoselective reactions in presence of aromatic amino groups
CN110950780A (en) * 2019-12-13 2020-04-03 河南润弘制药股份有限公司 Neostigmine methylsulfate-like compound, preparation method and application

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010130899A (en) * 2010-07-23 2012-01-27 Федеральное Государственное Учреждение "33 Центральный Научно-Исследовательский Испытательный Институт Министерства Обороны Российск METHOD FOR PRODUCING NEOSTIGMINE METHYL SULPHATE AND NEOSTIGMINE IODIDE
WO2017175238A1 (en) * 2016-04-07 2017-10-12 Neon Laboratories Limited Highly chemoselective reactions in presence of aromatic amino groups
CN110950780A (en) * 2019-12-13 2020-04-03 河南润弘制药股份有限公司 Neostigmine methylsulfate-like compound, preparation method and application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SATOSHI UEDA等: "Copper-Catalyzed Synthesis of Benzoxazoles via a Regioselective C-H Functionalization/C-O Bond Formation under an Air Atmosphere", 《J. ORG. CHEM》 *

Similar Documents

Publication Publication Date Title
CN109890790B (en) Preparation method of oseltamivir and isomers thereof
CA2604602A1 (en) Method for the preparation of pregabalin and salts thereof
CN110590635A (en) Preparation method of levetiracetam and intermediate thereof
US20160362391A1 (en) Improved Process for the Preparation of Pomalidomide and its Purification
KR20120128667A (en) A process for the preparation of lacosamide
EP2723709B1 (en) Manufacture of a triiodinated contrast agent
WO2011095110A1 (en) Intermediate compounds of lacosamide, preparation methods and uses thereof
JP2007537189A (en) Process for the preparation of perindopril or its salts
CN115353465A (en) Synthesis method of neostigmine methylsulfate
WO2017082396A1 (en) Method for producing lacosamide and intermediate thereof
CN115353466B (en) Preparation and purification method of neostigmine methosulfate
US20110319649A1 (en) Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide
CN115768747A (en) Synthesis of (2S, 5R) -5- (2-chlorophenyl) -1- (2 '-methoxy- [1,1' -biphenyl ] -4-carbonyl) pyrrolidine-2-carboxylic acid
CN102816083A (en) Preparation method of lacosamide
JP4190879B2 (en) A novel intermediate for the production of theanine
CN106661033B (en) The novel intermediates for being used to prepare the method for AZD5363 and using wherein
CN113024521B (en) Method for preparing emtrictinib
KR100310936B1 (en) A process for preparing N-(4-methylbenzenesulfonyl)-N'-(3-azabicyclo[3,3,0]octane)urea
US6699988B2 (en) Process for the preparation of N,N′-carbonylbislactams
CN117756882A (en) Preparation method of L-glutamyl-L-alanine
JP2022140107A (en) Method for producing 1,4-benzodiazepine compound
KR100834387B1 (en) Novel method for producing benzamide derivative and intermediate thereof
KR100566896B1 (en) Processes for the preparation of an optically active 5,6-dioxopiperazine-2-carboxylic acid derivative
CN113583021A (en) Synthesis method of spiropiperidine rifamycin
CN114163372A (en) Continuous preparation method of vildagliptin key intermediate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20221118